The SBFC Finance IPO has been open for subscription until today, August 7, while the Concord Biotech IPO will close its initial public offering tomorrow. Both mainboard issues, SBFC Finance IPO and Concord Biotech IPO, started accepting subscriptions last week. SBFC Finance IPO began the bidding process on August 3, while Concord Biotech IPO launched its issue on August 4.
Investors are hopeful for the next top-performing IPO, considering the stellar listing gains observed in Utkarsh SFB, IdeaForge, and Cyient DLM.
Finance IPO is a non-banking finance company (NBFC), whereas Concord Biotech IPO is a research & development biopharma company.
SBFC Finance IPO vs Concord Biotech IPO
The subscription for SBFC Finance IPO was opened on Thursday, August 3, and will be closed on Monday, August 7. The company has set the price band for the proposed initial public offer at ₹54 to ₹57 per equity share.
As per the Red Herring Prospectus (RHP), SBFC Finance IPO includes a fresh issuance of equity shares amounting to ₹600 crore and an offer for sale (OFS) of ₹425 crore. The total offer size of SBFC Finance IPO now stands at ₹1,025 crore.
The subscription for Concord Biotech IPO was opened on Friday, August 4, and will be closed on Tuesday, August 8. The company has set the price band for the IPO at ₹705 to ₹741 per equity share of face value ₹1 each.
Concord Biotech IPO, which is backed by Rekha Jhunjhunwala, comprises a pure offer-for-sale by Helix Investment Holdings of up to 20.93 million shares. The issue offer is priced at ₹1,550 crore at the upper band, and the firm is valued at ₹7,752 crore.